Nucala (mepolizumab) is now approved in Canada as an add-on to standard therapy for the treatment of adults with hypereosinophilic syndrome (HES) for greater than 6 months without an identifiable non-hematologic secondary cause.
GlaxoSmithKline plc announced the FDA has approved Nucala (mepolizumab) for the treatment of adult and paediatric patients aged 12 years and older with Hypereosinophilic Syndrome (HES) for at least six months without an identifiable non-haematologic secondary cause.
GlaxoSmithKline announced positive results from the pivotal study of Nucala (mepolizumab) in the treatment of patients living with Hypereosinophilic Syndrome...
Objective: To characterize the therapeutic effect of eosinophil depletion in patients with hypereosinophilic syndrome with varied eosinophilic gastrointestinal (GI) disorders.
This document aims to provide a pragmatic, practical guideline for the management of adults with pSS.
This guideline covers rehabilitation strategies for adults who have experienced a critical illness and stayed in critical care.
The goal of this guideline is to provide an evidence-based approach to the diagnosis, management, and prevention of bronchiolitis in children from 1 month through 23 months of age.
This guideline is restricted to GI endoscopy but we cover elective and acute or emergency procedures.
This guideline, relating to the provision of a percutaneously placed enteral tube feeding service, is focused upon a specific area of nutrition provision that has not been previously targeted.
This guideline covers identifying and caring for adults who are malnourished or at risk of malnutrition in hospital or in their own home or a care home.